A multicenter, retrospective study evaluating efficacy and safety of antibodies against PD-1 (pembrolizumab, nivolumab) or its ligand, PD-L1 (atezolizumab) in patients with metastatic uveal melanoma
Latest Information Update: 22 Jul 2016
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Uveal melanoma
- Focus Adverse reactions; Therapeutic Use
- 22 Jul 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology